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Introduction: Patients with CF experience pulmonary exacerbations. These are often initially empirically treated with intravenous antibiotics, with
antibiotic choice reﬁned after susceptibility testing.
Methods: We completed a 5-year retrospective review of children attending the Paediatric CF Unit, Nottingham. The respiratory sampling, anti-
biotic prescribing and susceptibility testing guidance were audited. Episodes were classiﬁed according to the concordance between the antibiotics
prescribed and antibiotic susceptibility testing.
Results: Of 52 patients who had previously isolated Pseudomonas aeruginosa, 103 antibiotic courses were commenced that coincided with an iso-
lation of P. aeruginosa. P. aeruginosa was fully susceptible, partially susceptible or fully resistant on 33%, 44.7% or 16.5% of occasions respec-
tively. The antibiotic prescriptions were never changed following antibiotic susceptibility testing. We found no association between change in
FEV1 (p=0.54), change in BMI (p=0.12) or time to next exacerbation (p=0.66) and concordance between antibiotic susceptibility and the anti-
biotics administered.
Conclusion: This study contributes to mounting evidence questioning the utility of routine antibiotic susceptibility testing.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Antibiotic; Susceptibility testing; Pseudomonas1. Introduction
The natural history of progression of lung disease in cystic
fibrosis (CF) usually consists of a sequential acquisition of
infecting organisms [2], the most significant acquisition being
infection with Pseudomonas aeruginosa. While early infection
with P. aeruginosa, may be eradicated by the expeditious use
of antibiotic therapy [3–5], chronic infection with P. aeruginosa
is accompanied by significant decline in clinical status, including
lung function [6]. Such patients experience pulmonary☆ Presented at: 34th European Cystic Fibrosis Society Conference, Hamburg
— June 2011 [1].
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doi:10.1016/j.jcf.2012.02.006exacerbations consisting of an increase in symptoms and reduc-
tion in lung function that are routinely treated with intravenous
antibiotics [7].
Conventionally, antibiotic selection has been directed by the
results of antibiotic susceptibility testing. However there is un-
certainty regarding the states in which the organism exists with-
in the CF lung and the antibiotic susceptibilities of the organism
growing in planktonic, adherent and biofilm states vary signifi-
cantly [8]. There is emerging evidence to suggest that the testing
of antibiotic susceptibility against ceftazidime and tobramycin
may not be associated with clinical response [9] and that when
routine testing is reduced, short-term outcomes appear to be unaf-
fected [10].
At the time of writing, the clinical guideline of Nottingham
Children's Hospital Children and Young Persons CF Unit re-
flects the strategy of many units in the UK in recommendingby Elsevier B.V. All rights reserved.
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Fig. 1. Flow diagram of patient/episode selection.
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of deterioration.When antibiotics are prescribed, routine antibiotic
susceptibility testing of respiratory cultures guides the prescrip-
tion. We wished to audit our practice against these guidelines
and evaluate the outcome of our service.
2. Method
We completed a retrospective case-note audit of patients at-
tending the Children and Young Persons CF Unit, Nottingham
UK for each attendance between January 2005 and November
2010. We identified those patients who had chronic pulmonary
infection with P. aeruginosa (as defined by greater than 50% of
months with samples positive for P. aeruginosa over the last
12 months) [12].
The adherence to the respiratory sampling, antibiotic suscep-
tibility testing and antibiotic prescribing guidance was audited.
We determined the effect of adherence to the guidance upon
outcome.
Our practice is to undertake respiratory sampling at the com-
mencement of a treatment course of antibiotics, with the initial
selection of antibiotics being either empirical or guided by the
most recent culture result from the previous clinical contact.
Antibiotics selection should then be refined once the results
of susceptibility testing are reported. Antibiotic susceptibility
testing is performed in our unit using disc diffusion testing
against a standard panel of antibiotics — ceftazidime, cipro-
floxacin, piptazobactam, meropenem, aztreonam, gentamicin,
amikacin, tobramycin and colistin. The isolation of multiple
strains of P. aeruginosa is identified by morphotype. The
BSAC (British Society of Antimicrobial Chemotherapy)
methods for antimicrobial susceptibility testing are used for in-
terpretation [13].
We planned to identify episodes where a strain ofP. aeruginosa
was isolated from a patient with CFwhich was later reported to be
resistant to the antibiotic(s) prescribed and where the antibiotics
were not changed. We classified episodes according to the con-
cordance between the antibiotics prescribed and antibiotic sus-
ceptibility profiles of the isolated organism. If the organism was
‘fully susceptible’ or ‘fully resistant’ to both antibiotics adminis-
tered this was recorded (i.e. the organism was reported to be sus-
ceptible to both antibiotics empirically commenced — ‘fully
susceptible’; or reported to be resistant to both antibiotics com-
menced — fully resistant). In cases where the organism was
reported as susceptible to one antibiotic but resistant to the
other in the combination, this was recorded as ‘partially suscepti-
ble’. In cases where more than one strain of P. aeruginosa was
identified, the antibiotic profile was determined to be fully suscep-
tible (or fully resistant) if the antibiotics prescribed matched (or
otherwise) the susceptibility profile of the isolated organism. The
combination of two strains of bacteria was considered to be ‘par-
tially susceptible’ in all combinations other than the situation
where the bacteria were fully susceptible or fully resistant (e.g.
in the case of one strain being fully susceptible but the other par-
tially susceptible, the combination was categorised as ‘partially
susceptible’). Changes in FEV1, BMI (body mass index) during
treatment and the time to next exacerbation were compared.Where BMI data was missing this was calculated from the last
clinic height and the current weight. Two groups of analyses
were performed; the first using the unit of analysis (UoA) as the
first episode for each patient so that each patient would only con-
tribute once, and for the second the unit of analysis was each exac-
erbation, to ensure that no data were lost. Differences between
groups were tested using Kruskal–Wallis test.
3. Results
In the five year period, 52 patients had P. aeruginosa isolated
at least once, of whom 4 had been transferred to adult services
and 8 patients had not experienced a pulmonary exacerbation or
their notes were ‘missing’. The remaining 40 patients had re-
ceived 306 antibiotic courses combined, of which 169 (55.2%)
were given intravenously. Of these, 23 patients had received
103 courses of intravenous antibiotic therapy that followed an
isolation of P. aeruginosa either on admission or at a clinic atten-
dance that prompted admission. This group forms the basis of the
further analysis. (Fig. 1).
Of the episodes where P. aeruginosa was isolated and trea-
ted with intravenous antibiotics, the average age at first intrave-
nous antibiotic course in the study period was 9 years (range
1–14 years) with patients receiving an average of 4 intravenous
courses (range 1–17) in the period of interest.
Reports for antibiotic susceptibility testing were available
for 97 (94.2%) episodes. In no case was the antibiotic prescrip-
tion changed upon receipt of the antibiotic susceptibility report.
Of the 103 episodes, the organism was found to be fully
BMI change during course of treatment
Fu
lly
 su
sc
ep
tib
le
Pa
rtia
lly
 su
sc
ep
tib
le
Fu
lly
 re
sis
tan
t 
Fu
lly
 su
sc
ep
tib
le
Pa
rtia
lly
 su
sc
ep
tib
le
Fu
lly
 re
sis
tan
t
-2
0
2
4
6 UoA Patient UoA Exacerbation
Concordance between bacterial
sensitivity profile
and empirical antibiotics commenced
B
M
I c
ha
ng
e 
(kg
/m
2 )
p=0.78 p=0.12
Fig. 3. BMI change over the duration of an antibiotic treatment course with
categorisation of antibiotic concordance (UoA — unit of analysis).
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resistant on 17 (16.5%) and partially susceptible on 46
(44.7%) of occasions. On three occasions the antibiotic pre-
scription was changed mid-way through an intravenous treat-
ment course. On two occasions this was due to a poor clinical
response, however the antibiotic change did not alter the con-
cordance categorisation. On a third occasion a family member
wished the antibiotics to be changed and again, the antibiotic
was changed to another to which the organism was similarly
resistant.
Considering the outcomes of FEV1 (% predicted) (Fig. 2),
BMI (Fig. 3) or time to next exacerbation/next intravenous
treatment course (Fig. 4), there was no association between out-
come and concordance between antibiotic susceptibility profile
and the antibiotics administered.
Analysing all 103 episodes, the outcome in terms of change
in FEV1 percent predicted was not associated with the concor-
dance between sensitivity profile and the antibiotics prescribed
(p=0.5353), neither was outcome dependent upon antibiotic
concordance for change in BMI (p=0.1202), or time to next
exacerbation of intravenous antibiotic course (p=0.6603).
Analysing the data using the patient as the unit of analysis so
that each patient contributes only their first treatment course to
the data set, neither FEV1 (p=0.1759), BMI (p=0.7785) or time
to next exacerbation or intravenous antibiotic course (p=0.2239)
was associated with antibiotic susceptibility concordance.FEV1 change during course of
treatment
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Fig. 2. FEV1 change over the duration of an antibiotic treatment course with
categorisation of antibiotic concordance (UoA — unit of analysis).
Time to next exacerbation
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Fig. 4. Time to next exacerbation/course of iv antibiotics categorised by antibiotic
concordance (UoA— unit of analysis).
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We found that our practice adhered closely to the guideline
recommending respiratory sampling at each clinical contact and
that antibiotic susceptibility testing was performed in 94.2% of
cases. However on no occasion was the empirical antibiotic chan-
ged upon receipt of the antibiotic susceptibility profile. We found
that, despite 66% of antibiotic courses consisting of antibiotics to
which the organism was not fully susceptible, the antibiotic con-
cordance was not associated with clinical outcome in terms of
lung function (FEV1), BMI or time to the next exacerbation.
A similar study consisting of a retrospective analysis of pa-
tient data from the control group of a randomised trial of in-
haled tobramycin, restricted the prescription of intravenous
antibiotics to ceftazidime and tobramycin. They found no corre-
lation between antibiotic susceptibility to tobramycin and cefta-
zidime and clinical outcome [9]. In their practice in an adult CF
unit, Etherington et al. [10] rationalised antibiotic susceptibility
testing to be performed only at the onset of antibiotic treatment,
upon suspicion of clinical treatment failure or routinely if not
tested in the previous three months [10]. They analysed the re-
sponse to treatment before and after the change in practice and
found no significant difference.
The antibiotic susceptibility reports in these studies detail sus-
ceptibility profiles for antibiotics in isolation. In order to answer
the question of whether combination antibiotic susceptibility test-
ing conferred a clinical benefit, a randomised trial compared com-
bination susceptibility testing with conventional testing. There
was no significant difference in clinical or bacteriological out-
come [14].
In order to more closely reflect the anticipated mode of
growth of the organism within the CF lung, attempts have
been made to consider antibiotic regimens based on biofilm
susceptibilities. Generating simulated antibiotic regimens
based on biofilm and conventional susceptibility testing yields
different antibiotic selections that on some occasions were con-
tradictory [15]. The results of clinical trials evaluating biofilm
susceptibility-directed therapy are awaited.
Our report is likely to represent a significant proportion of
clinical practice in the UK and reflects the ‘real world situation’.
Not only was the response to all antibiotic selections included,
but we were also able to determine the effect for patients who re-
ceive intravenous antibiotics at regular intervals, irrespective of
whether they would meet criteria of an infective exacerbation.
We are also the first to report such findings in the paediatric
population.
Our findings are limited by the small number of patients
who contribute to the data set. However, these patients repre-
sent a wide spectrum of severity of disease and the correspond-
ing analysis at the patient level, serves to support our findings
and reduce the likelihood that we have encountered a unit of
analysis error.
The concern regarding the applicability of conventional an-
tibiotic susceptibility continues to increase and further ques-
tions arise as a result. The most likely explanation for the
poor association between susceptibility and response is that
the mode of growth of the organism is difficult to represent invitro. In addition, inconsistencies in the diagnosis of pulmonary
exacerbations [16] and uncertainty about under which circum-
stances and for what duration antibiotics should be used [17]
add to the lack of confidence in our current antibiotic manage-
ment of infection in CF.
The effective management of pulmonary exacerbations is
critical to the continued improvements in CF care, and is an
area in which we currently fall short. Twenty-five percent of
patients experiencing an exacerbation do not recover their base-
line lung function after treatment [18] leading to the relentless
deterioration in clinical state over time. The administration of
intravenous antibiotics is also associated with toxicity, selecting
for resistant strains and significant costs both for patients and
healthcare systems. The judicious use of antibiotics is required
however we currently are unable to more effectively target the
causative organism. A focus for research is the search for a
valid in vitro model of the in vivo condition and further under-
standing of how the organism behaves in the clinical setting. In
the meantime the mounting evidence questioning the utility of
routine susceptibility testing suggests that a more refined ap-
proach should be considered.
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